“As a part of Eris Groups’ internal structuring of the holdings, the Company has transferred 100% of its holdings in the below mentioned entities to Eris Therapeutics Limited (“ETL”), a wholly-owned subsidiary: Eris Oaknet Healthcare Private Limited (“EOHPL”), wholly-owned subsidiary Aprica Healthcare Limited (“AHL”), wholly-owned subsidiary,” Eris Lifesciences said in a regulatory filing.
Also Read: Eris Life to acquire nine dermatology brands from DRL for Rs 275 crore
The agreement for the transfer was executed on March 6, 2025, with the transaction expected to be completed by March 31, 2025. The total consideration for the transfer amounts to ₹861.91 crore.
Eris Lifesciences manufactures, markets, and sells generic drugs. The Company provides a wide range of products in chronic and acute therapy segments, which includes capsules, tablets, and sachets.
Shares of Eris Lifesciences Ltd ended at ₹1,274.15, up by ₹46.35, or 3.78%, on the BSE.
Also Read: Franklin Templeton hikes stake in Eris Lifesciences, buys shares for ₹109 crore
